Skip to main content

Table 1 Clinical efficacy inputs

From: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

All patients with non-squamous histology

PEM

N = 205

DOC

N = 194

Median survival, months1 (95% CI)

9.30 (7.80-9.7)

8.00 (6.30-9.30)

Overall survival hazard ratio (95% CI)1

0.78 (0.61-1.00)

Median PFS, months1

3.10

3.00

PFS hazard ratio (95% CI)1

0.82 (0.66-1.02)

Response rates (%) (Complete response + partial response)2

10.78

8.81

Response rates (95% CI)

(7.25-15.80)

(5.59-13.66)

Proportion of responders by cycle 2 (%)3

45.83

  1. Source: 1 Scagliotti et al, 2009 [10]; 2 Data on file, Eli Lilly, 2008; 3 Taken from JMEI data, number of responders by cycle 2/total responders (22/48)
  2. PEM: pemetrexed; DOC: docetaxel; CI: confidential interval; PFS: progression-free survival
  3. Table 1 presents the clinical efficacy inputs that drive the model.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us